{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T01:40:44Z","timestamp":1775353244636,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13550-019-0505-x","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T12:02:30Z","timestamp":1560427350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET\/CT: SUVmax versus total lung glycolysis"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-1644","authenticated-orcid":false,"given":"Milou C.","family":"Schimmelpennink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriane D. M.","family":"Vorselaars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth G. M.","family":"Keijsers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"issue":"4","key":"505_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jama.2011.10","volume":"305","author":"MC Iannuzzi","year":"2011","unstructured":"Iannuzzi MC, Fontana JR. Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305(4):391\u20139. \n                    https:\/\/doi.org\/10.1001\/jama.2011.10\n                    \n                  .","journal-title":"JAMA."},{"issue":"6","key":"505_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1309\/AJCPNC7STHG0FWMP","volume":"134","author":"D De Smet","year":"2010","unstructured":"De Smet D, Martens GA, Berghe BV, et al. Use of likelihood ratios improves interpretation of laboratory testing for pulmonary sarcoidosis. Am J Clin Pathol. 2010;134(6):939\u201347. \n                    https:\/\/doi.org\/10.1309\/AJCPNC7STHG0FWMP\n                    \n                  .","journal-title":"Am J Clin Pathol."},{"issue":"1","key":"505_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1378\/chest.124.1.186","volume":"124","author":"JC Grutters","year":"2003","unstructured":"Grutters JC, Fellrath JM, Mulder L, Janssen R, van den Bosch JM, van Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: A clinical evaluation. Chest. 2003;124(1):186\u201395 doi: S0012-3692(15)36009-8 [pii].","journal-title":"Chest."},{"issue":"4","key":"505_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1515\/jomb-2016-0017","volume":"35","author":"S Popevic","year":"2016","unstructured":"Popevic S, Sumarac Z, Jovanovic D, et al. Verifying sarcoidosis activity: Chitotriosidase versus ACE in sarcoidosis - a case-control study. J Med Biochem. 2016;35(4):390\u2013400. \n                    https:\/\/doi.org\/10.1515\/jomb-2016-0017\n                    \n                  .","journal-title":"J Med Biochem."},{"issue":"7","key":"505_CR5","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00259-009-1097-x","volume":"36","author":"RG Keijsers","year":"2009","unstructured":"Keijsers RG, Verzijlbergen FJ, Oyen WJ, et al. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging. 2009;36(7):1131\u20137. \n                    https:\/\/doi.org\/10.1007\/s00259-009-1097-x\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"12","key":"505_CR6","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.rmed.2011.08.012","volume":"105","author":"RL Mostard","year":"2011","unstructured":"Mostard RL, Voo S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET\/CT in persistent symptomatic sarcoidosis. Respir Med. 2011;105(12):1917\u201324. \n                    https:\/\/doi.org\/10.1016\/j.rmed.2011.08.012\n                    \n                  .","journal-title":"Respir Med."},{"issue":"6","key":"505_CR7","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1378\/chest.07-1178","volume":"132","author":"AS Teirstein","year":"2007","unstructured":"Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132(6):1949\u201353.","journal-title":"Chest."},{"issue":"10","key":"505_CR8","first-page":"1571","volume":"47","author":"Y Nishiyama","year":"2006","unstructured":"Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47(10):1571\u20136.","journal-title":"J Nucl Med."},{"issue":"Suppl 1","key":"505_CR9","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S\u201350S. \n                    https:\/\/doi.org\/10.2967\/jnumed.108.057307\n                    \n                  .","journal-title":"J Nucl Med."},{"issue":"1","key":"505_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00259-011-1934-6","volume":"39","author":"S Liao","year":"2012","unstructured":"Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39(1):27\u201338. \n                    https:\/\/doi.org\/10.1007\/s00259-011-1934-6\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"4","key":"505_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1034\/j.1399-3003.1999.14d02.x","volume":"14","author":"U Costabel","year":"1999","unstructured":"Costabel U, Hunninghake GW. ATS\/ERS\/WASOG statement on sarcoidosis. sarcoidosis statement committee. american thoracic society. european respiratory society. world association for sarcoidosis and other granulomatous disorders. Eur Respir J. 1999;14(4):735\u20137.","journal-title":"Eur Respir J."},{"issue":"2","key":"505_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: Version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354. \n                    https:\/\/doi.org\/10.1007\/s00259-014-2961-x\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"505_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1183\/09031936.00227014","volume":"46","author":"AD Vorselaars","year":"2015","unstructured":"Vorselaars AD, Crommelin HA, Deneer VH, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175\u201385. \n                    https:\/\/doi.org\/10.1183\/09031936.00227014\n                    \n                  .","journal-title":"Eur Respir J."},{"issue":"1","key":"505_CR14","first-page":"44","volume":"35","author":"H Adams","year":"2018","unstructured":"Adams H. rooij R van, van moorsel CH, spee-dropkova M, Grutters1JC, keijsers RG. volumetric FDG PET analysis of global lung inflammation: New tool for precision medicine in pulmonary sarcoidosis? sarcoidosis vasc diffuse lung dis. 1 apr.2018;35(1):44.","journal-title":"sarcoidosis vasc diffuse lung dis."},{"key":"505_CR15","volume-title":"Practical statistics for medical research","author":"DG Altman","year":"1991","unstructured":"Altman DG. Practical statistics for medical research. Boca Raton, FL: Chapman & Hall\/CRC; 1991."},{"issue":"1","key":"505_CR16","first-page":"37","volume":"31","author":"JP Cremers","year":"2014","unstructured":"Cremers JP, Van Kroonenburgh MJ, Mostard RL, et al. Extent of disease activity assessed by 18F-FDG PET\/CT in a dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):37\u201345.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"issue":"10","key":"505_CR17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2967\/jnumed.112.104380","volume":"53","author":"D Sobic-Saranovic","year":"2012","unstructured":"Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. The utility of 18F-FDG PET\/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53(10):1543\u20139. \n                    https:\/\/doi.org\/10.2967\/jnumed.112.104380\n                    \n                  .","journal-title":"J Nucl Med."},{"issue":"2","key":"505_CR18","first-page":"123","volume":"28","author":"RG Keijsers","year":"2011","unstructured":"Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):123\u20139.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-019-0505-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13550-019-0505-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-019-0505-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T23:05:06Z","timestamp":1591916706000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-019-0505-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["505"],"URL":"https:\/\/doi.org\/10.1186\/s13550-019-0505-x","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,13]]},"assertion":[{"value":"8 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Our study involves human participants. The study was approved by the investigational review board of St Antonius Hospital Nieuwegein (registration number LTME\/Z-12.33 and acronym ORATS). According to this protocol, no informed consent is needed. The study was in accordance with the Helsinki Declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants for whom identifying information is included in this article (Figs.\u00a0 and ): R05.08A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"54"}}